Clarient introduces new breast cancer test

Clarient, a provider of anatomic pathology and molecular testing services, has launched a new breast cancer test that helps physicians identify the probability of a patient’s cancer recurring and assess the need for chemotherapy.

The new prognostic test, Clarient Insight Dx breast cancer profile, has been clinically validated for women with early-stage, hormone-receptor-positive breast cancer. Unlike other assays used to determine the likelihood of recurrence, the Clarient Insight Dx breast cancer profile uses a combination of pathology risk factors and molecular markers to categorize patients as either high or low risk, said Clarient.

The Clarient Insight Dx breast cancer profile combines three traditional pathology staging risk factors with seven key molecular markers. Staging factors are tumor size, tumor grade, and lymph node status. Molecular markers include ER, PR, HER2, EGFR, BCL2, p53, and MYC. The information is then combined with a proprietary algorithm to produce a risk score that assists pathologists and oncologists in clinical decision-making, the company added.

Ron Andrews, CEO of Clarient, said: With the launch of the Clarient Insight Dx breast cancer profile, we move one step closer to fulfilling our vision of transforming breast cancer from a deadly disease to a chronic disorder.

At Clarient, we currently perform a range of prognostic testing such as ER, PR and HER2, and we also have a deep menu of molecular pathway tests that enable pathologists to ascertain a thorough understanding of each individual tumor. The ability to now further test these patients for risk of recurrence strengthens our service offering to our pathology clients, as well as enhances our overall competitive position in the breast cancer testing market.